{"name":"IRCCS San Raffaele","slug":"irccs-san-raffaele","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"\"Drug:Carvedilol\" and \"Drug:Ivabradine\"","genericName":"\"Drug:Carvedilol\" and \"Drug:Ivabradine\"","slug":"drug-carvedilol-and-drug-ivabradine","indication":"Other","status":"marketed"},{"name":"Antiarrhythmic Drug Therapy","genericName":"Antiarrhythmic Drug Therapy","slug":"antiarrhythmic-drug-therapy","indication":"Other","status":"marketed"},{"name":"Insulin glargine plus insulin analogues","genericName":"Insulin glargine plus insulin analogues","slug":"insulin-glargine-plus-insulin-analogues","indication":"Other","status":"marketed"},{"name":"L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract","genericName":"L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract","slug":"l-methionine-hibiscus-sabdariffa-and-boswellia-leaf-extract","indication":"Other","status":"phase_1"},{"name":"Myelostim","genericName":"Myelostim","slug":"myelostim","indication":"Other","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Atazanavir/ritonavir monotherapy","genericName":"Atazanavir/ritonavir monotherapy","slug":"atazanavir-ritonavir-monotherapy","indication":"HIV-1 infection (monotherapy maintenance in virologically suppressed patients)","status":"phase_3"},{"name":"Defibrotide Injection","genericName":"Defibrotide Injection","slug":"defibrotide-injection","indication":"Hepatic Veno-Occlusive Disease","status":"phase_2"},{"name":"NUCS","genericName":"NUCS","slug":"nucs","indication":"Treatment of COVID-19","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"99m-TC-PSMA-I&S","genericName":"99m-TC-PSMA-I&S","slug":"99m-tc-psma-i-s","indication":"Diagnostic imaging of prostate cancer","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"PEG-IFNa 2a","genericName":"PEG-IFNa 2a","slug":"peg-ifna-2a","indication":"Chronic hepatitis C","status":"phase_3"}]}],"pipeline":[{"name":"\"Drug:Carvedilol\" and \"Drug:Ivabradine\"","genericName":"\"Drug:Carvedilol\" and \"Drug:Ivabradine\"","slug":"drug-carvedilol-and-drug-ivabradine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"99m-TC-PSMA-I&S","genericName":"99m-TC-PSMA-I&S","slug":"99m-tc-psma-i-s","phase":"phase_2","mechanism":"99m-TC-PSMA-I&S is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) for diagnostic imaging of prostate cancer.","indications":["Diagnostic imaging of prostate cancer"],"catalyst":""},{"name":"Antiarrhythmic Drug Therapy","genericName":"Antiarrhythmic Drug Therapy","slug":"antiarrhythmic-drug-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atazanavir/ritonavir monotherapy","genericName":"Atazanavir/ritonavir monotherapy","slug":"atazanavir-ritonavir-monotherapy","phase":"phase_3","mechanism":"Atazanavir/ritonavir inhibits HIV protease to prevent viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition.","indications":["HIV-1 infection (monotherapy maintenance in virologically suppressed patients)"],"catalyst":""},{"name":"Defibrotide Injection","genericName":"Defibrotide Injection","slug":"defibrotide-injection","phase":"phase_2","mechanism":"Phosphodiesterase inhibitor","indications":["Hepatic Veno-Occlusive Disease"],"catalyst":""},{"name":"Insulin glargine plus insulin analogues","genericName":"Insulin glargine plus insulin analogues","slug":"insulin-glargine-plus-insulin-analogues","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract","genericName":"L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract","slug":"l-methionine-hibiscus-sabdariffa-and-boswellia-leaf-extract","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Myelostim","genericName":"Myelostim","slug":"myelostim","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NUCS","genericName":"NUCS","slug":"nucs","phase":"phase_3","mechanism":"NUCS is a small molecule that targets the SARS-CoV-2 main protease.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"PEG-IFNa 2a","genericName":"PEG-IFNa 2a","slug":"peg-ifna-2a","phase":"phase_3","mechanism":"PEG-IFNa 2a is a pegylated form of interferon alpha-2a, which works by stimulating the body's immune system to fight viral infections and cancer cells.","indications":["Chronic hepatitis C","Chronic hepatitis B","Multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOQkMwT1VXTkEtOEgwQWVUMW42WkxjT291S0dXdDVCQ21PcG5sYm9STUhmODdSRi1YckJ0QzdzSWM3Q3NrUVFZMEhnM0RFNUpuOHFwT3NQV2RJMzA0S1dDcnpqOU4zR2JtMzRHa0RxRDlaQ0xfQVY3NldTUl9JeXBZbFdEYUJHRFRjcWZSMktQemplaHNGemt6dTk4ZDRaQkZRVzlSdDgxRmM0RmltY2JPQk80MEItSnV5VWtNUi1HM0x2czVNUDBwREw2emtqOVlQVjZvejA1Qkk3UTVPODljX2NCTmlpZDNqeFlyQnZkTlA3bG1RajZR?oc=5","date":"2026-02-12","type":"pipeline","source":"Business Wire","summary":"Thetis Pharmaceuticals Expands Scientific Advisory Board with Leading Experts in Inflammatory Bowel Disease - Business Wire","headline":"Thetis Pharmaceuticals Expands Scientific Advisory Board with Leading Experts in Inflammatory Bowel Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOVGpaU0NMeFA5ci1tMFZLYWFrT1JwdHp5VmgyQld5SDl5UExyZXBROFlnTVliM3hBcmhNT1NUdC16XzFyUTBsdVNYbURJWUFSdmh5SlgxUV9OYzl3eWFxVDJIOV9BclA3dC1ZZkdDajBSQlY1bllXNTFUTWdSRm1TeHRTN0dBZUpwbE9xU0VFYkNsVHF2cV90ckExbm5kN1E0dTMzZnUxRjVLUTZUNTlRdXdNMmxoOVNzaUxHT3o1OC0?oc=5","date":"2026-01-21","type":"pipeline","source":"Il Sole 24 ORE","summary":"A drug originally developed for sleep disorders re-emerges as a candidate against multiple sclerosis - Il Sole 24 ORE","headline":"A drug originally developed for sleep disorders re-emerges as a candidate against multiple sclerosis - Il Sole 24 ORE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNeEJlNms4UnJKZHk2cDhsaTNlMWN0R2VOMXZQSjM5UWFYVzl6aDJuT3NpQlYzR0RSNWlVamNyaGhUSVBVR1d4bEdpdzh0cTRzVUpoVnduWE5TNlJDdkJPa0R4RlRlQU4xS0RTWVN6WlM1Y3BZUi1BWFRJZnFuV1dUX3ZVajhLb043ZTdwMVdWWl9BOVcwUjZtMnhKRUJrMHU1NDJvMg?oc=5","date":"2026-01-16","type":"pipeline","source":"The Pharma Letter","summary":"EC authorization for Waskyra for Wiskott-Aldrich syndrome - The Pharma Letter","headline":"EC authorization for Waskyra for Wiskott-Aldrich syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB5R3B3ZE9KdElqaDhxQ3piX2JBclFzWkJraWZQc1RRdlFmejh1enU5N2RRLUpfT21Kc29peFZHb1ZIdlFobi1tbFdodHhrTjZpSThMN1Z1YlVWY0M1SGgw?oc=5","date":"2025-08-29","type":"pipeline","source":"Nature","summary":"Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era - Nature","headline":"Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE9ZWnF1Q0pBRlhUbjdhdnFFRDFFbHlWeTRTVzhPYzR1cV91S01jdE1Ka21mQnBkZXVqcDBRbHZFdFliYUg1c2M4bUxaN1A5dEZyV1pLc0lMaDA1TjJuODE1RE53?oc=5","date":"2025-08-07","type":"pipeline","source":"ACS Publications","summary":"Polydopamine Nanoparticles as a Potential Non-Pharmaceutical Antioxidant Tool against Mitochondrial Disorders - ACS Publications","headline":"Polydopamine Nanoparticles as a Potential Non-Pharmaceutical Antioxidant Tool against Mitochondrial Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA4QWtINWlWRXR1UFBFR19XZ3BIYjNIaElfaUp4aXpnbHZ3SDQzMnVLYzVZU0hicVNZZ2RpVEM3RllQTnhGU0RZaE1hVUx2OWR4YlBPQ19pYVo4WjVyQ2tz?oc=5","date":"2025-07-01","type":"trial","source":"Nature","summary":"BRIDGE: a multi-stakeholder workstream focused on assessing new clinical endpoints in ophthalmology clinical trials [Building Research Innovations and Developing Global Endpoints] | Eye - Nature","headline":"BRIDGE: a multi-stakeholder workstream focused on assessing new clinical endpoints in ophthalmology clinical trials [Bui","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOalJMd3BMMlo3Yk84azhUV0NKZDF2UlBud2JnVDNSNHk2LWw5TU0xQnpROUJQUnlIQlg3NTBUZHVpRmVKNGdGdzNPY08yRnJTeHh5bHdHZ0dmYWhmcEtLOVNQdEhwZ2QzV2hsRkZZeC1RclFKXzQwZkxWS1B6RnctVjJQX25leExPTl9UNDJ3MnBMbmdyUnhCUmVyamJFTjRHTVJpQQ?oc=5","date":"2025-03-03","type":"regulatory","source":"PharmTech.com","summary":"EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia - PharmTech.com","headline":"EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-15","type":"pipeline","source":"PR Newswire UK","summary":"San Raffaele Hospital (Milan, Italy): new, promising results from the first patients implanted with the spinal neurostimulator. A new, high-frequency spinal stimulation protocol gives hope for motor r","headline":"San Raffaele Hospital (Milan, Italy): new, promising results from the first patients implanted with the spinal neurostim","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOMkcwSVhIQ0oxcnQxQWdaRkJCVDRaRGoySmVYNjVvQnpqOGQwb3FSc2dvdGtzMkhLQ2V1VDhUVXpTY1VjZ3dIMlYxUkpjOXU4V3pydVRjSGNxakN3Y2xZUDZ6Qmo3eUp4NlB6YlQ4NjFadHQ4T0ZLS0Rfb3Y1OWQ0N0N4eG5zSHVLV0tDUTdreVpsa2pXREJfZ2ZDa1dwczZKR29fTnI5Zk9Mc3BXYzNtNnVlNA?oc=5","date":"2023-12-19","type":"trial","source":"PMLiVE","summary":"Newel Health launches study of digital therapeutic for Parkinson’s disease - PMLiVE","headline":"Newel Health launches study of digital therapeutic for Parkinson’s disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE81b1o3ZnVVWHVBNlFIUzlTelZfU3lza0xnUDU3TGRBSnhFMGwtS0RrT09WYUhUZTdwRXhSZXdadDZPR2NfeVV4R2NWZVQ4SFJuVXRyRy1taTJBdTliSTVOdlE0QjVEVTJBYU1R?oc=5","date":"2023-09-15","type":"pipeline","source":"Wiley Online Library","summary":"Hypertrophic obstructive cardiomyopathy caused by Fabry disease: implications for surgical myectomy - Wiley Online Library","headline":"Hypertrophic obstructive cardiomyopathy caused by Fabry disease: implications for surgical myectomy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOYlltVElUOUZpbWFyMmJIQ0RzalI4eG9TY1VOOUNxcHFHeEl1LTlnZGRqRGZzNDE3cEQ2Z0Noa0hFb0l5dkdjbklqcm13Unpfb3VKSWkwV0NKUU1sSFUwdzJFVEhpMzNMaGtCRkVwR3dCbmxYeVRPUXd5STJtNHRKakJ0NVR1cEw4cy01bw?oc=5","date":"2023-05-14","type":"pipeline","source":"Eurasia Review","summary":"Low Levels Of Vitamin D Linked To Long COVID - Eurasia Review","headline":"Low Levels Of Vitamin D Linked To Long COVID","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNRkpzSEtsWmRWV0xqdExFWlJpTFl3N0xIU2xLTDV0N2JpakZZdkREMGlTVFZFa0NxaG5oZ0NCXzR0WlZuNDNJYXRUa1kzYjJFTWVFUjBfZy1KN1Ftcmo3anhvWlpXb0l1UjhubFZJWUdvbER2YzRkbkV1enNERFY4ZWVTelVBRFZCb09BXzdqYUw5R2tDU2VBN2lkQnFoWklHM1dEcXFzbFNfNFVyQTRwcURaWmtROFRNY1A5dg?oc=5","date":"2019-04-29","type":"trial","source":"Intellia Therapeutics - investor relations","summary":"Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy - Intellia Therapeutics - investor relations","headline":"Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American S","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"marketed":3,"phase_2":3,"phase_3":3,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}